Dual RXR Agonists and RAR Antagonists Based on the Stilbene Retinoid Scaffold
摘要:
Arotinoids containing a C5,C8-diphenylnaphthalene-2-y1 ring linked to a (C3-halogenated) benzoic acid via an ethenyl connector (but not the corresponding naphthamides), which are prepared by Horner-Wadsworth-Emmons reaction of naphthaldehydes and benzylphosphonates, display the rather unusual property of being RXR agonists (15-fold induction of the RXR reporter cell line was achieved at 3- to 10-fold lower concentration than 9-cis-retinoic acid) and RAR antagonists as shown by transient transactivation studies. The binding of such bulky ligands suggests that the RXR ligand-binding domain is endowed with some degree of structural elasticity.
DOI:
10.1021/ml400521f
作为产物:
描述:
3,4-亚甲基二氧溴苯 、 亚磷酸三乙酯 在
silica gel 、 甲醇乙酸乙酯 作用下,
反应 2.0h,
以to obtain the entitled compound (300 mg)的产率得到methyl 3-fluoro-4-(diethoxyphosphoryl)methylbenzoate
The current invention provide novel retinoid compounds and methods for their synthesis, methods of treating or preventing emphysema, cancer and dermatological disorders and pharmaceutical compositions suitable for the treatment or prevention of emphysema, cancer and dermatological disorders.
Modulation of Retinoic Acid Receptor Subtypes by 5- and 8-Substituted (Naphthalen-2-yl)-based Arotinoids
作者:Susana Álvarez、Michele Lieb、Claudio Martínez、Harshal Khanwalkar、Fátima Rodríguez-Barrios、Rosana Álvarez、Hinrich Gronemeyer、Angel R. de Lera
DOI:10.1002/cmdc.201500150
日期:2015.8
described dihydronaphthalene arotinoids with the same substitution pattern. Transactivation studies in this series revealed an absence of synergy between small halogen atoms (F, Cl) at C3 and the groups at C5 or C8, as had been observed on some of the dihydronaphthalene analogues. Instead, non‐halogenated 4‐(2‐naphthamido)benzoic acid derivatives transactivated toward the RARβ subtype in preference to the
The present invention provides an imidazopyridine compound represented by formula (I),
wherein R
1
and R
2
each independently represent a C
1-6
alkyl group et al; R
3
and R
4
each independently represent a hydrogen atom, a methyl et al; Ar
1
is a divalent substituent representing a monocyclic or bicyclic, 3- to 8-membered aromatic or aliphatic heterocyclic group et al; Ar
2
represents an aromatic carbocyclic group, or an aromatic heterocyclic group; W represents —(CH
2
)
m
et al, and m indicates an integer of from 0 to 10. This compound acts as a melanin concentrating hormone receptor antagonist, and is useful as treating agents for obesity.
Aryliden-1-azacycloalkane und Arylalkyl-1-azacycloalkane, deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung
申请人:Dr. Karl Thomae GmbH
公开号:EP0596326A1
公开(公告)日:1994-05-11
Die Erfindung betrifft Aryliden-1-azacycloalkane und Arylalkyl-1-azacycloalkane der allgemeinen Formel
in der
n, m, p, A, W1, W2, X, Y und R1 bis R11 wie im Anspruch 1 definiert sind, deren Isomeren, Isomerengemische und deren Salze, welche wertvolle Eigenschaften aufweisen, insbesondere eine inhibitorische Wirkung auf die Cholesterolbiosynthese ausüben.
The present invention provides an imidazopyridine compound represented by formula (I),
wherein R1 and R2 each independently represent a C1-6 alkyl group et al; R3 and R4 each independently represent a hydrogen atom, a methyl et al; Ar1 is a divalent substituent representing a monocyclic or bicyclic, 3- to 8-membered aromatic or aliphatic heterocyclic group et al; Ar2 represents an aromatic carbocyclic group, or an aromatic heterocyclic group; W represents -(CH2)m et al, and m indicates an integer of from 0 to 10. This compound acts as a melanin concentrating hormone receptor antagonist, and is useful as treating agents for obesity.